MetaBre journal publications

2004

  • Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. Ahmed Boucharaba, Claire-Marie Serre,Sandra Grès, Jean Sébastien Saulnier-Blache, Jean-Claude Bordet,Julien Guglielmi, Philippe Clézardin,and Olivier Peyruchaud (INSERM) J.Clin.Invest. (2004) 114, 1714 –1725.
  • Bcl-xL-mediated changes in metabolic pathways of breast cancer cells from the survival in the blood stream to organ-specific clinical manifest metastasis. España E, Martin B, Chiva C, Aragues R, Andreu D, Oliva B, Sierra A (IRO). Breast Cancer Res Treat. (2004) 87:33-44.
  • Lysophosphatidic acid: a new link between breast cancer and bone metastasis. Boucharaba A, Serre CM, Saulnier-Blache JS, Bordet JC, Guglielmi J, Clezardin P, Peyruchaud O (INSERM) J. Clin. Invest. (2004) 114:1714-25.

2005

  • A novel protein kinase C alpha-dependent signal to ERK1/2 activated by alphaVbeta3 integrin in osteoclasts and in Chinese Hamster Ovary (CHO) cells Rucci N, DiGiacinto C, Orrù L , Millimaggi D, Baron R, Teti A. (UNIVAQ, PSK), J Cell Sci. (2005) 118:3263-75
  • Human Breast Tumors Override the Antiangiogenic Effect of Stromal Thrombospondin-1 In Vivo. Fontana A, Filleur S, Guglielmi J, Frappart L, Bruno-Bossio G, Boissier S, Cabon F, Clézardin P (INSERM) Int J Cancer. (2005) 116:686-91.
  • Bcl-x(L)-mediated changes in metabolic pathways of breast cancer cells: from survival in the blood stream to organ-specific metastasis. Espana L, Martin B, Aragues R, Chiva C, Oliva B, Andreu D, Sierra A. (IRO) Am J Pathol. (2005) 167:1125-37
  • Breast cancer metastasis: when, where, how? Eccles S, Paon L (ICR). Minireview in The Lancet (2005) 365: 1006-07

2006

  • Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide-3 kinase signalling in human breast cancer cells. Beloueche-Babari M, Jackson LE, Al-Saffar NMS, Eccles SA, Workman PW, Leach MO, Ronen SM (ICR) Mol Cancer Therapy (2006) 5:187-96
  • Under-expression of transcriptional regulators is common in breast cancer cells with ubiquitous metastasis Mendez O, Martin B, Sanz R, Aragues R, Moreno V, Oliva B, Stresing V, Sierra A (IRO). Carcinogenesis (2006) in press.
  • Inhibition of protein kinase c-Src reduces breast cancer metastases and increases survival in mice Rucci N, Recchia I, Angelucci A, Alamanou M, Del Fattore A, Fortunati D , Šuša M, Fabbro D, Bologna M, Teti A (UNIVAQ) submitted J. Pharmacol Exp Therapy
  • Biological pathways contributing to organ-specific phenotype of breast cancer cells metastasizing to brain Martin B, Aragues R, Sanz R, Oliva B, Martinez A Sierra A (IRO) submitted to Cancer Res
  • Gene profiling analysis of tissue-specific metastases from human breast cancer. T. Landemaine, A. Jackson, A. Teti, A. Sierra, T. Garcia, K. Driouch, R. Lidereau. EJC supplements, 4, 2, 139.
  • Transcriptome analysis reveals an osteomimetic phenotype for human bone metastatic breast cancer cells. A. Bellahcene, R. Bachelier, C. Detry, R. Lidereau, P. Clezardin, V. Castronovo. EJC supplements, 4, 2, 163.
  • Biological functions of brain metastasis from breast cancer. R. Sanz, B. Martin, R. Aragues, T. Landemaine, A. Jackson, K. Driouch, M. Gil, M. Brell, S. Boluda, A. Sierra. EJC supplements, 4, 2, 165.
  • In vitro models of breast cancer lymph node metastasis. L Paon, S.A. Eccles. EJC supplements, 4, 2, 169.
  • Redox regulation of Prx II and Prx III in breast cancer. E. Baltziskueta, V. Stresing, A. Sierra. EJC supplements, 4, 2, 170.
  • Characterisation of brain metastases from human breast cancer in nude mice: longitudinal MR studies at 7 Tesla. B. Martin, R. Simoes, A. Martinez, R. Sanz, S. Cerdan, C. Arus, A. Sierra. EJC supplements, 4, 2, 171.
  • Improvement of breast cancer metastasis-free survival by anti c-Src therapy. N. Rucci, I. Recchia, A. Angelucci, M. Alamanou, A. Del Fattore, D. Fortunati, M. Susa, D. Fabbro, A. Teti. EJC supplements, 4, 2, 173.
  • Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice. Implications for therapy. N. Rucci, I. Recchia, A. Angelucci, M. Alamanou, A. Del Fattore, D. Fortunati, M. Susa, D. Fabbro, M. Bologna, A. Teti. J Pharmacol Exp Ther. 2006 Apr 20; [Epub ahead of print]

2007

  • Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Bellahcene A, Bachelier R, Detry C, Lidereau R, Clezardin P, Castronovo V.Breast Cancer Res Treat. 2007 Jan;101(2):135-48. Epub 2006 Oct 7.
  • Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases.Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, Clement-Lacroix P, Clezardin P. Cancer Res. 2007 Jun 15;67(12):5821-30.
  • Identification of specific reachable molecular targets in human breast cancer using a versatile ex vivo proteomic method. Castronovo V, Kischel P, Guillonneau F, de Leval L, Defechereux T, De Pauw E, Neri D, Waltregny D. Proteomics. 2007 Apr;7(8):1188-96.